RxDoctor Payments Data

Madeline Emmi, PA

Medical · Orchard Park, NYNPI 1922785443

Payments from drug & device makers

$4,564in general payments, 2019–2025

Across 128 payments — averaging $35.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$331
  • Pfizer$257
  • Gilead$250
  • Sanofi$165
  • plus $368 from 5 others

What the payments were for

  • Food & beverage$4,48098%
  • Education$842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,564 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$31,632
Medicare patients
206
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide50$36,529
XifaxanRifaximin14$31,338
Mesalamine32$13,453
Mesalamine DrMesalamine15$7,166
Pantoprazole Sodium237$7,126
Dexlansoprazole DrDexlansoprazole18$4,626
Colestipol Hcl44$4,341
Famotidine351$3,347
Budesonide EcBudesonide15$2,250
CholestyramineCholestyramine (With Sugar)20$2,177
Ursodiol14$1,987
Rabeprazole Sodium87$1,828
Esomeprazole Magnesium25$1,443
Omeprazole124$1,342
Sucralfate24$1,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,891$36,52950 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$331$31,33814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.

Other medical in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →